{
  "id": 10863310,
  "title": "Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill",
  "url": "https://urgent.news/2026/09/30/zasocitinib-delivered-superior-efficacy-versus-deucravacitinib-in-new",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-30T05:04:03.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/zasocitinib-delivered-superior-efficacy-versus-deucravacitinib-in-new-phase-3-head-to-head-results-reinforcing-potential-to-deliver-rapid-and-durable-skin-clearance-in-a-convenient-once-daily-pill"
  },
  "original_language": "en",
  "account": null,
  "summary": "Head-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete skin clearance observed as early as week 8 More than 2.5 times as many patients treated with zasocitinib achieved complete skin clearance (PASI 100) at week 16 compared to deucravacitinib […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Takeda's Zasocitinib Shows Superior Skin Clearance In Phase 3 Psoriasis Trial",
        "url": "https://urgent.news/2026/09/30/takedas-zasocitinib-shows-superior-skin-clearance-in-phase-3",
        "published": "2026-09-30T06:03:53.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}